Press Releases

OriGene Technologies has been Selected as the 2023 Bioz Stars Award Winner in Various Product Categories
January 29^th, 2023 - Rockville, Maryland, USA - OriGene is excited to announce that it has been selected as the 2023 Bioz Stars Award Winner in the following categories: Cloning, Vectors, & CRISPR. In the cloning..(Full Press Release)

OriGene Technologies Updates Logo for Rebranding Its Expansion from Genomics to Proteomics
Rockville, MD - Jan 7th, 2022 - OriGene updates its logo, signifying its evolvement from genomic to proteomic market. The logo modification includes an addition of antibody/antigen image to the previous logo.. (Full Press Release)

OriGene Technologies and EdiGene Announce Joint Development of Genome Wide Knockout Cell Lysates
Rockville, MD – November 21, 2016 – OriGene Technologies, a large supplier of genecentric research tools, today announced that it has entered into a multi-year strategic agreement with EdiGene (Beijing, China) to develop genome wide knockout cells from commonly used laboratory cell lines.. (Full Press Release)

ALK UltraMAB® Antibody (OTI1A4) Outperform D5F3 Antibody, Successfully Demonstrating Higher Sensitivity in NSCLC Immunohistochemistry Diagnostics
Rockville, MD – April 14, 2016. A pair of recently published studies shed light on the highly interesting area on detection of ALK expression among NSCLC patients by IHC. One study was conducted by NordiQC (Aalborg, Denmark),. (Full Press Release)

OriGene & Dako Establish Multi-year Antibody Development Collaboration and Announce Commercial License Grant for “Ultra-Specific” Monoclonal Antibody for ALK Detection
Rockville, MD. February 4th, 2016 – OriGene Technologies, Inc., announced today that it has entered into a multi-year antibody development collaboration featuring its proprietary UltraMAB? technology platform and granted to Dako, an Agilent Technologies company (Santa Clara, CA), a worldwide non-exclusive commercial license to OriGene’s mouse anti-ALK monoclonal antibody clone OTI1A4 for research and diagnostics use within the immunocytochemistry and immunohistochemistry fields.. (Full Press Release)

OriGene Technologies Awarded Phase II SBIR Contract to Develop High-Affinity, Anti-Peptide Monoclonal Antibodies for SISCAPA Assays
Rockville, MD – January 7th, 2016 - OriGene Technologies, Inc. (OriGene), a leading manufacturer of high quality antibodies and gene-centric tools, announced today that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.. (Full Press Release)

OriGene Technologies Strengthens Antibody Portfolio by Acquiring Acris Antibodies GmbH
ROCKVILLE, MD – Oct 28, 2015 – OriGene Technologies, Inc. (“OriGene”), an industry leader of genome wide products for research and diagnostic applications, announced today that it has acquired Acris Antibodies GmbH (“Acris Antibodies”), a provider of antibodies and other life science related products.. (Full Press Release)

SDIX, LLC, an OriGene Company, Achieves Significant Milestone with ISO 13485:2003 Certification
Newark, DE – April 7, 2015 SDIX, LLC, a leading immuno-solution company, specializing in the design, development and manufacture of high quality antibodies for the diagnostic, pharmaceutical and biotechnology industries, today announced it has received ISO 13485:2003 certification.. (Full Press Release)

OriGene Launches Genome-wide Gene-knockout Kits Using CRISPR Platform Rockville, MD - April 30, 2014 - OriGene Technologies (Rockville, MD), a large supplier of gene-centric research tools, launches a new product line of gene-knockout kits using CRISPR technologies. The new products provide a complete solution for researchers to knock out a human gene at the chromosomal level. (Full Press Release)

OriGene Technologies Acquires BioCheck
ROCKVILLE, MD -- Feb 26, 2014 – OriGene Technologies, Inc. (“OriGene”), one of the industry leaders in producing genome wide products for research and diagnostic applications, announced today that it has acquired BioCheck, Inc., a provider of innovative immunodiagnostic test kits and custom immunoassay development for the world-wide health care and research markets.. (Full Press Release)

OriGene Technologies awarded NCI contract to develop high affinity anti-peptide antibodies for SISCAPA SRM assays in partnership with the Institute for Systems Biology
ROCKVILLE, MD--(Jan 30, 2014) – OriGene Technologies, Inc. (“OriGene”), one of the industry leaders in producing genome wide products for research and diagnostic applications, has been awarded a contract from the National Cancer Institute (NCI) to develop high affinity anti-peptide antibodies for SISCAPA assays.. (Full Press Release)

Latest Cell Publication of OriGene and Peking University Collaborative Discovery of New iPS Reprogramming Factors
Rockville, MD. May 30th, 2013 - Scientists from Peking University, China and OriGene Technologies jointly published that multiple lineage specifier genes can replace OCT4 and SOX2 during reprogramming, the core regulators of cell pluripotency.. (Full Press Release)